Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

Trial Profile

Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms VOYAGE 1
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 25 Oct 2019 Results of pooled analysis assessing the relative efficacy of guselkumab and ustekinumab for maintenance therapy of moderate-to-severe plaque psoriasis using individual patient data (IPD) from randomized controlled trials (VOYAGE 1, VOYAGE 2, NAVIGATE) published in the British Journal of Dermatology
    • 17 Oct 2019 According to a Janssen media release, VOYAGE 1 is part of a comprehensive TREMFYA Phase 3 clinical development program in psoriasis that includes two additional Phase 3 trials, VOYAGE 2 and NAVIGATE, as well as ECLIPSE, which is a Phase 3b study of TREMFYA vs. secukinumab.
    • 17 Oct 2019 According to a Janssen media release, the new long-term data from the open-label period of this study are being presented at the 39th Fall Clinical Dermatology Conference in Las Vegas, Nevada.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top